Search

everythinglearnresearchcommunity

for

Search:↓

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Late puberty may slightly lower prostate cancer risk, baldness is not linked to overall risk but less so with aggressive types, ibuprofen use may increase risk, and vitamins show no effect on risk.

5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

Cancer development is like natural selection, involving mutated cells and environmental factors.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.

Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Dutasteride may help shrink prostate cancer tumors.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Finasteride treats hair loss but may affect prostate cancer detection.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.

Dutasteride works better than finasteride for preventing and treating prostate cancer.